Why Real-World Evidence Is Failing HEOR Teams at the Moment It Matters Most
Real-world evidence was supposed to solve one of health technology assessment's most persistent problems. Randomised controlled trials, however rigorously designed, capture what a therapy does under controlled conditions in selected patient populations over defined time horizons. They do not capture what happens when that therapy is used by the full spectrum of patients who present in clinical practice, managed by clinicians with varying levels of experience, across health systems with different treatment protocols and support infrastructure. Payers have always known this. They have always wanted evidence that bridges the gap between the trial population and the real-world population they are being asked to fund treatment for. Real-world evidence, generated from registries, electronic health records, claims databases, and observational studies, was positioned as the answer. And to a significant extent, it has delivered on that promise. The volume of published real-world evidence in most major therapeutic areas has grown dramatically over the past decade. The problem is not the evidence. The problem is what happens to it when HEOR teams try to integrate it into systematic reviews, economic models, and HTA submissions alongside conventional trial data. That integration process is where real-world evidence most frequently fails to deliver its potential value. And it is where artificial intelligence is beginning to create a genuinely different kind of capability.
The Integration Problem Nobody Warned Us About
When systematic review methodology was formalised in the 1990s and refined through the 2000s, it was designed primarily with randomised controlled trial evidence in mind. The hierarchy of evidence that underpins conventional systematic review practice places RCTs at the apex for a reason. Their design controls for confounding in ways that observational studies cannot. The methodological tools for assessing RCT quality, extracting their data consistently, and synthesising their findings statistically are mature, widely understood, and well-supported by existing guidance. Real-world evidence does not fit comfortably into this framework. Observational studies come in multiple designs, each with different confounding risks and methodological considerations. Quality assessment tools differ across study types. Data extraction requires capturing methodological details that standard extraction templates were not designed to accommodate. Statistical synthesis of heterogeneous observational evidence raises questions that conventional meta-analytic methods were not built to address. The result is that HEOR teams attempting to conduct systematic reviews that integrate RWE alongside trial evidence face methodological complexity that manual workflows handle poorly and inconsistently. Some teams exclude observational evidence entirely to preserve methodological simplicity. Others include it without the rigorous quality assessment it requires. Neither approach serves payers well, and both create submission vulnerabilities that HTA bodies are increasingly alert to. Systematic literature review software designed to handle methodologically heterogeneous evidence addresses this challenge at the infrastructure level. Rather than forcing all evidence types through a single extraction and quality assessment framework designed for RCTs, AI-powered platforms can apply appropriate methodological tools to different evidence types simultaneously, maintaining consistency within each category while enabling integrated synthesis across the full evidence landscape. Pienomial's evidence intelligence architecture is built around this methodological flexibility, recognising that the future of health technology assessment belongs to organisations that can work fluently across the full spectrum of evidence rather than those that restrict themselves to the methodological comfort zone of conventional trial synthesis.
Where AI Changes What Is Achievable
The methodological complexity of integrating real-world evidence into systematic reviews is not just a quality challenge. It is a capacity challenge. Properly assessing the quality of a large cohort study requires different expertise and different tools than assessing a randomised trial. Extracting the relevant methodological and outcome data from a registry analysis is a more complex task than extracting from a trial publication with a standardised reporting structure. When a systematic review must handle hundreds of publications across multiple evidence types simultaneously, the manual resource requirement becomes genuinely prohibitive. AI for drug development HEOR functions is changing what is achievable within practical timelines and resource constraints. Machine learning models trained on methodological quality assessment can apply consistent, documented evaluation criteria across large volumes of observational studies at a pace that manual reviewers cannot approach. Natural language processing tools can extract structured data from the varied formats and reporting conventions that characterise real-world evidence publications, converting unstructured text into synthesis-ready outputs without requiring each document to be manually read and transcribed by a researcher. An AI assistant for HEOR teams working with real-world evidence provides particular value in the quality assessment phase. One of the most resource-intensive and methodologically demanding aspects of RWE integration is assessing confounding risk, selection bias, and outcome measurement validity across diverse observational study designs. An AI assistant for HEOR teams that applies validated quality assessment frameworks consistently across large study sets ensures that this critical methodological step is conducted rigorously, regardless of team size or timeline pressure. Systematic literature review software that natively supports the full range of real-world evidence study types, from retrospective cohort analyses to patient registry studies to electronic health record-based analyses, gives HEOR teams a methodologically sound foundation for the kind of comprehensive evidence synthesis that payers increasingly demand.
The Synthesis Challenge Across Evidence Types
Even after individual studies have been identified, quality-assessed, and extracted, the synthesis challenge remains formidable. How should RWE findings be combined with trial evidence when the two are not directly comparable? How should evidence synthesis handle the situation where real-world effectiveness estimates differ substantially from trial efficacy estimates, as they frequently do? How should economic models incorporate both types of evidence in ways that are transparent, defensible, and reflective of genuine clinical practice? Automated evidence synthesis that is specifically configured for methodologically heterogeneous evidence provides structured approaches to these questions rather than leaving teams to develop bespoke solutions for each review. When synthesis methods are pre-specified, consistently applied, and automatically documented, the resulting evidence integration is reproducible and auditable in ways that ad hoc approaches are not. AI for drug development evidence synthesis that spans both trial and real-world evidence also enables more sophisticated exploration of the gap between efficacy and effectiveness, one of the questions payers most frequently raise when evaluating submissions. When AI can systematically characterise how real-world outcomes compare to trial outcomes across a therapeutic area, that analysis becomes a proactive submission strength rather than a reactive response to payer queries. An AI literature review tool that handles RWE integration as a standard capability rather than a special case produces evidence packages where trial and real-world evidence are connected analytically rather than presented in parallel silos. That connection is where the most persuasive value arguments are built, because it demonstrates not just that a therapy works but that it continues to work when the controlled conditions of the trial give way to the complexity of routine clinical practice. Pienomial's commitment to building AI for drug development evidence capabilities that work across the full methodological spectrum reflects a recognition that payer decision-making has already moved beyond trial-only evidence. The organisations best equipped to win the reimbursement conversations of the next decade are those whose evidence infrastructure has moved there too. Automated evidence synthesis that genuinely integrates real-world and trial evidence is the capability that will define who leads and who follows in the health technology assessment landscape ahead.
Frequently Asked Questions
1. How does AI for drug development support real-world evidence integration in systematic reviews? AI for drug development platforms apply appropriate quality assessment frameworks across diverse observational study designs simultaneously, enabling methodologically rigorous integration of real-world evidence alongside trial data within systematic review workflows. 2. Why is systematic literature review software essential for handling heterogeneous evidence types? Systematic literature review software with native support for observational study designs ensures quality assessment, extraction, and synthesis are conducted consistently across RCTs and real-world evidence, producing integrated evidence packages that HTA bodies can evaluate with confidence. 3. What is automated evidence synthesis across trial and real-world evidence? Automated evidence synthesis applies pre-specified, consistently documented methods across methodologically heterogeneous evidence, connecting trial efficacy and real-world effectiveness findings in reproducible, auditable outputs that strengthen HTA submissions. 4. How does an AI assistant for HEOR teams improve observational study quality assessment? An AI assistant for HEOR teams applies validated confounding risk and bias assessment frameworks consistently across large volumes of observational studies, ensuring methodological rigour that manual workflows cannot sustain under typical timeline and resource constraints. 5. What makes an AI literature review tool better suited to real-world evidence than manual approaches? An AI literature review tool extracts structured data from the varied reporting formats of real-world evidence publications automatically, converting unstructured text into synthesis-ready outputs faster and more consistently than manual extraction allows. 6. How does Pienomial's platform support methodologically heterogeneous evidence synthesis? Pienomial's evidence intelligence platform applies appropriate methodological frameworks across different evidence types simultaneously, enabling HEOR teams to conduct integrated systematic reviews that meet the comprehensive evidence standards increasingly demanded by payers and HTA bodies. 7. Can systematic literature review software help bridge the efficacy-effectiveness gap for payers? Yes. Systematic literature review software that integrates real-world and trial evidence systematically enables structured analysis of how outcomes compare across settings, giving payers the transparency they need to evaluate real-world value claims with confidence.